Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Conditions
Brief summary
This trial is conducted in Asia. The aim of this trial is to investigate the efficacy of biphasic insulin aspart 30 on postprandial glycaemic control.
Interventions
DRUGbiphasic insulin aspart
Sponsors
Novo Nordisk A/S
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Type 1 or 2 diabetes for at least 3 months * Stabilised on current treatment with premixed human insulin for at least 4 weeks * Body mass index (BMI) between 18-40 kg/m2 * HbA1c below 13.0% * Able and willing to perform self-blood glucose monitoring
Exclusion criteria
* The receipt of any investigational drug within the last three months prior to this trial * Has a history of drug abuse or alcohol dependence within the last 5 years * Active proliferative retinopathy requiring laser or surgical intervention within the last year * Recurrent major hypoglycaemia as judged by the Investigator * Known or suspected allergy to trial product or related product
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-hr postprandial plasma glucose (PPPG) excursion | after 12 weeks of treatment |
Secondary
| Measure | Time frame |
|---|---|
| HbA1c | — |
| Fasting plasma glucose | — |
Countries
China
Outcome results
None listed